Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3034934 | 0.85 | ACE2 (0.47) | ACE2 | |
| SCHEMBL3024811 | 0.83 | ACE2 (0.44) | ACE2LMNA | |
| SCHEMBL3043253 | 0.81 | ACE2 (0.37) | ACE2LMNA | |
| SCHEMBL3024352 | 0.79 | ACE2 (0.32) | ACE2LMNA | |
| SCHEMBL94561 | 0.78 | — | — | |
| SCHEMBL3042489 | 0.78 | CYP3A4 (0.39) | LMNACYP3A4L3MBTL1 | |
| SCHEMBL51236 | 0.77 | LMNA (0.31) | LMNA | |
| SCHEMBL8812631 | 0.77 | LMNA (0.52) | LMNACYP3A4 | |
| SCHEMBL532293 | 0.77 | LMNA (0.52) | LMNACYP3A4 | |
| SCHEMBL8810599 | 0.77 | LMNA (0.52) | LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854877-B1 | Process for the deacylation of cyclic lipopeptides | ASTELLAS PHARMA INC (JP) | 2012-02-08 | — | — | EP | disclosed |
| EP-2172546-A1 | Process for the deacylation of cyclic lipopeptides | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-7629366-B2 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| EP-0885957-B1 | PROCESS FOR THE DEACYLATION OF CYCLIC LIPOPEPTIDES | ASTELLAS PHARMA INC (JP) | 2009-08-12 | — | — | EP | disclosed |
| EP-1854877-A2 | Process for the deacylation of cyclic lipopeptides | Astellas Pharma Inc. (JP) | 2007-11-14 | — | — | EP | disclosed |
| EP-1666587-A1 | Cyclic lipopeptide acylase | Astellas Pharma Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-20060100252-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-7037938-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| EP-1546086-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-6825003-B2 | Cyclic lipopeptide acylase | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-H1638-H | CYCLIC HEXAPEPTIDE | FURUTA TAKAHISA (JP) | 1997-03-04 | — | — | US | disclosed |
| EP-0741697-A1 | AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE A2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-11-13 | — | — | EP | disclosed |
| US-5569646-A | TREATMENT OF PNEUMONIA; MICROBIOCIDES, FUNGICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-29 | — | — | US | disclosed |
| EP-0462531-B1 | Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0729974-A1 | Cyclic polypeptide with antibiotic activity and a process for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995019959-A1 | AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE A2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-27 | — | — | WO | disclosed |
| EP-0644199-A1 | Cyclic antimicrobial peptides and preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-22 | — | — | EP | disclosed |
| US-5376634-A | Microbiocides | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-12-27 | — | — | US | disclosed |
| EP-0486011-A2 | Pharmaceutical composition against Pneumocystis carinii | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-05-20 | — | — | EP | disclosed |
| EP-0462531-A2 | Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100252-A1 | Aminoalcohol derivatives | H1-0, CHRM2, CHRM1 | ACE2 551/4885LMNA 3590/4885CYP3A4 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.